The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > REGULATORY
REGULATORY
- Chuikyo Offers No Objection to MHLW Proposal on SaMD Reimbursement Criteria
November 21, 2023
- MHLW Notification Outlines 2-Stage Approval Scheme for SaMD
November 21, 2023
- Provide “One-Stop Services” to Facilitate Multiregional Clinical Trials: Expert
November 21, 2023
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
- LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
November 21, 2023
- MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
November 21, 2023
- Pilot Sales of Emergency Contraceptives without Prescription to Start on Nov. 28
November 20, 2023
- Japan to Adopt Generic Company Indices for Drug Pricing on Pilot Basis from FY2024
November 20, 2023
- Pharma Fiercely Opposes Proposed CEA Cut into Drug Base Price: Chuikyo Hearing
November 20, 2023
- Japan Agrees to Buy 1.4 Million Doses of Daiichi Sankyo’s COVID Vaccine
November 17, 2023
- LDP Raises Stable Drug Supply as Major Topic of FY2024 Budget Formulation
November 17, 2023
- Meiji’s mRNA Vaccine, Daiichi’s XBB.1.5 Jab Up for Nov. 27 PAFSC Session
November 17, 2023
- Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi
November 16, 2023
- Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
- Vyvgart to Get 7.8% Price Cut, Tiny Reductions for Dysval, Retevmo: CEA
November 16, 2023
- Imfinzi Faces Price Slash of 25%, Polivy 15% in February: Quarterly Re-Pricing
November 16, 2023
- Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
- MHLW Plans Joint Surprise Onsite Inspections by PMDA and Prefectural Govts
November 16, 2023
- MHLW Panel Pins Hope on PMDA’s Overseas Offices to Foster Global Appeal of Japan Market
November 16, 2023
- LDP Pharma Study Group Calls for Expanding Sakigake Premium, Creating New Premium
November 15, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…